1. Home
  2. EYE vs JANX Comparison

EYE vs JANX Comparison

Compare EYE & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Vision Holdings Inc.

EYE

National Vision Holdings Inc.

HOLD

Current Price

$27.29

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.21

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYE
JANX
Founded
1990
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
EYE
JANX
Price
$27.29
$13.21
Analyst Decision
Strong Buy
Buy
Analyst Count
9
12
Target Price
$29.00
$57.36
AVG Volume (30 Days)
1.2M
2.0M
Earning Date
02-25-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,921,355,000.00
$10,000,000.00
Revenue This Year
$9.58
N/A
Revenue Next Year
$4.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.33
N/A
52 Week Low
$10.45
$13.26
52 Week High
$30.02
$47.58

Technical Indicators

Market Signals
Indicator
EYE
JANX
Relative Strength Index (RSI) 48.27 30.47
Support Level $25.61 $13.68
Resistance Level $30.02 $14.34
Average True Range (ATR) 1.20 0.47
MACD 0.11 0.38
Stochastic Oscillator 37.98 26.61

Price Performance

Historical Comparison
EYE
JANX

About EYE National Vision Holdings Inc.

National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: